Adaptive Biotechnologies Corporation operates primarily through two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The company's flagship clinical product, clonoSEQ, is an FDA-authorized next-generation sequencing test used to detect and monitor minimal residual disease in patients with certain blood-based cancers. Its Immune Medicine segment features the immunoSEQ platform, which provides immunosequencing services and tools to academic researchers and biopharmaceutical companies for drug discovery and clinical trials. Additionally, Adaptive collaborates with strategic partners, such as Genentech and Microsoft, to develop personalized therapies and early disease detection diagnostics. By leveraging its massive clinical immunomics database, the company aims to transform how diseases are diagnosed and treated.
